Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial

Inclusion Criteria:

To be included in the study, you must meet the following criteria:

- Follicular NHL, grades 1 or 2 confirmed by a biopsy sample

- 18 years of age or older

- Evidence of disease progression at time of study entry

- Must have had at least one previous chemotherapy regimen and not more than two
previous chemotherapy regimens.

- Patients who have received previous rituximab are eligible as long as progression
occurred more than six months following completion of previous rituximab therapy.

- Measurable or evaluable disease

- Able to perform activities of daily living without considerable assistance

- Adequate bone marrow, kidney, and liver function

- Signed informed consent obtained prior to initiation of any study-specific procedures
or treatment.

Exclusion Criteria:

You cannot participate in the study if any of the following apply to you:

- Treatment with more than two previous chemotherapy regimens

- Prior treatment with bevacizumab or other similar agents

- Progressive NHL less than 6 months after receiving previous rituximab

- More than 1 prior treatment with investigational agents within 4 weeks prior to
entering this study

- Spread of NHL to brain or nervous system

- History of any other uncontrolled or significant disease or medical condition that
may put them at high risk for treatment complications with these agents

Please note: There are additional inclusion/exclusion criteria. The study center will
determine if you meet all of the criteria. If you do not qualify for the trial, study
personnel will explain the reasons. If you do qualify, study personnel will explain the
trial in detail and answer any questions you may have. You can then decide if you wish to
participate.